For millions of people managing type 2 diabetes, high blood pressure is a near-constant companion. The two conditions overlap so frequently that treating one without accounting for the other is nearly impossible. That intersection is now drawing fresh scrutiny after researchers flagged a potential problem with one of the most commonly prescribed drug classes in this patient population.
A large observational study presented at the 2026 European Renal Association Congress in Glasgow analyzed data from more than 31,000 adults with type 2 diabetes treated between 2016 and 2021. All participants were already receiving two kidney-protective therapies, and just under 40% were also taking dihydropyridine calcium channel blockers, known as DCCBs.
The findings were striking. DCCB use was associated with a 33% higher risk of major adverse kidney events compared to other blood pressure treatments used in the same population. Major adverse kidney events were defined as a significant decline in kidney filtration function or progression to end-stage kidney disease.
DCCBs work by relaxing blood vessels and are frequently used as second-line therapies in people with diabetic kidney disease. Common examples include amlodipine, nifedipine, and felodipine.
What the kidney risk finding actually means
Lead researcher Dr. Timna Agur from Tel Aviv University put it plainly: Our findings raise important questions about whether these medications are always the best option for patients already receiving modern kidney-protective therapies.
That question carries real weight. The study was observational, meaning it identified an association rather than a direct cause. The findings have not yet been published in a peer-reviewed journal, and researchers are careful to note that DCCBs remain valuable medications with well-documented cardiovascular benefits. A 2022 study comparing nearly 10,000 DCCB users to a similar number of non-users with type 2 diabetes actually suggested DCCBs could reduce the risk of advanced chronic kidney disease. The science, in other words, is still unsettled.
What is not unsettled is the urgency of managing both conditions. Hypertension is twice as common in people with type 2 diabetes as in the general population, and both conditions are independent risk factors for coronary artery disease, kidney failure, and congestive heart failure. Leaving either untreated carries serious consequences.
Can patients ever stop blood pressure medication?
The new research has renewed a conversation many patients are already having with their doctors: whether it is possible to come off blood pressure medication entirely. According to Dr. Rigved Tadwalkar, a consultative cardiologist, it is uncommon. Patients with mild hypertension, a recent diagnosis, or meaningful lifestyle improvements may have a path to reducing or eliminating medication, but only under close medical supervision.
Abruptly stopping blood pressure medication is not a safe option. Doing so can trigger rebound hypertension, where blood pressure spikes to levels higher than where the patient started. Any changes to a regimen need to be gradual, monitored, and directed by a physician.
For some patients, the better move is not stopping medication but switching it. Different drugs within the same treatment category can carry meaningfully different risk profiles, and finding one that controls blood pressure without unwanted side effects is often the more productive goal.
Lifestyle changes that move the needle on blood pressure
Medication aside, lifestyle interventions remain one of the most powerful tools available for managing hypertension. Preventive cardiology dietitian Michelle Routhenstein regularly works with patients who reduce or eliminate medications through sustained dietary and behavioral changes.
The DASH diet, which emphasizes high-potassium, low-sodium eating patterns and prioritizes fruits, vegetables, whole grains, and lean proteins, is among the most evidence-supported dietary approaches for lowering blood pressure. Pairing that with consistent physical activity, particularly resistance training, healthy weight management, stress reduction, and quality sleep can compound the benefit significantly.
Addressing sleep apnea is another factor that often gets overlooked. Left untreated, it keeps blood pressure chronically elevated even in people who are otherwise doing everything right.
The bigger picture for diabetes and hypertension patients
None of this means patients should start second-guessing their prescriptions on their own. Hypertension is shaped by genetics, age, and a full constellation of individual health factors. Lifestyle changes that work dramatically for one person may barely move the numbers for another.
What the new DCCB research reinforces is that medication decisions in patients with type 2 diabetes and kidney disease deserve more precision. Doctors and patients benefit from reviewing the full picture, especially as newer protective therapies are introduced and the risk profile of older medications comes into sharper focus. Anyone with questions about their current regimen should bring them to a healthcare provider who can evaluate the individual circumstances.
